Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 1.00 |
| ▸ | FNTA | P49354 | 6/20 | 0.42 |
| ▸ | FNTB | P49356 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapitant SCHEMBL6437147 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL14071561 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL121135 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL13575759 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL30695498 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL6908668 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL7768046 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL8543936 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8543712 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8956844 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| EP-0799056-B1 | USE OF A NK-1 RECEPTOR ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | disclosed |
| US-6180624-B1 | BY ADMINISTERING A COMBINATION OF A MORPHOLINE OR THIOMORPHOLINE TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| US-6162805-A | Use of an NK-1 receptor antagonist and an SSRI for treating obesity | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-19 | — | — | US | disclosed |
| US-6090819-A | Use of NK-1 receptor antagonists for treating mania | MERCK SHARP & DOHME, LTD. (GB) | 2000-07-18 | — | — | US | disclosed |
| EP-0799056-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LTD. (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996020009-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR1 45/4885FNTA 4439/4885FNTB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.